20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Larimar Therapeutics Inc (LRMR) operates in the BIOTECHNOLOGY industry and is headquartered in Bala Cynwyd, United States with about 71 employees. Its market capitalization is roughly $257 million. In the fiscal year ended 2025-12-31, LRMR reported $0M in revenue and ($166M) in net income.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | — | — | — | — | — | — | — |
| Gross Profit | — | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | — | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Income (EBIT) | ($179M) | ($172M) | ($91M) | ($42M) | ($37M) | ($50M) | ($43M) | ($23M) | ($63M) | ($54M) | ($57M) | ($74M) | ($36M) | ($14M) | ($14M) | ($13M) |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | ($173M) | ($166M) | ($81M) | ($37M) | ($34M) | ($50M) | ($42M) | ($23M) | ($61M) | ($52M) | ($58M) | ($74M) | ($37M) | ($14M) | ($14M) | ($13M) |
| Net Margin % | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | ($172M) | ($165M) | ($80M) | ($37M) | ($36M) | ($50M) | ($43M) | ($23M) | ($61M) | ($53M) | ($57M) | ($73M) | ($36M) | ($14M) | ($14M) | ($13M) |
| Earnings Per Share (EPS) | $-2.01 | $-2.27 | $-1.32 | $-0.84 | $-1.33 | $-2.93 | $-3.56 | $-7.43 | $-22.85 | $-22.76 | $-25.44 | $-33.32 | $-15.14 | $-6.44 | $-6.37 | $-6.04 |
| Shares Outstanding (M) | 104M | 73M | 61M | 44M | 26M | 17M | 12M | 3M | 3M | 2M | 2M | 2M | 2M | 2M | 2M | 2M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | $0M | — | $0M | $0M | $0M | $0M |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($34M) | ($31M) | ($64M) | ($49M) | ($28M) | ($31M) | ($31M) | ($18M) |
| Operating Margin % | — | — | — | — | — | — | -6492.3% | — |
| Net Income | ($33M) | ($30M) | ($62M) | ($48M) | ($26M) | ($29M) | ($29M) | ($15M) |
| Net Margin % | — | — | — | — | — | — | -5980.1% | — |
| EBITDA | ($33M) | ($30M) | ($62M) | ($48M) | ($26M) | ($29M) | ($29M) | ($15M) |
| Earnings Per Share (EPS) | $-0.32 | $-0.35 | $-0.73 | $-0.61 | $-0.41 | $-0.46 | $-0.45 | $-0.24 |
| Shares Outstanding (M) | 104M | 85M | 85M | 78M | 64M | 64M | 64M | 64M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($156M) | ($113M) | ($71M) | ($33M) | ($28M) | ($42M) | ($42M) | ($23M) | ($51M) | ($44M) | ($52M) | ($60M) | ($28M) | ($15M) | ($14M) | ($12M) |
| Capital Expenditures (CapEx) | $0M | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $1M | $1M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($156M) | ($113M) | ($71M) | ($34M) | ($28M) | ($42M) | ($42M) | ($23M) | ($52M) | ($44M) | ($53M) | ($60M) | ($28M) | ($15M) | ($14M) | ($12M) |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($44M) | ($45M) | ($39M) | ($29M) | ($19M) | ($27M) | ($22M) | ($25M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($44M) | ($45M) | ($39M) | ($29M) | ($19M) | ($27M) | ($22M) | ($25M) |
| FCF Margin % | — | — | — | — | — | — | -4563.1% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $165M | $146M | $200M | $96M | $126M | $79M | $105M | $5M | $122M | $106M | $132M | $189M | $118M | $38M | $11M |
| Cash & Cash Equivalents | $93M | $85M | $33M | $27M | $27M | $70M | $68M | $1M | $49M | $41M | $32M | $36M | $58M | $36M | $10M |
| Total Liabilities | $38M | $68M | $28M | $14M | $16M | $14M | $15M | $6M | $28M | $27M | $10M | $20M | $13M | $3M | $3M |
| Total Debt (Short + Long-Term) | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $9M | $21M | $20M | $4M | $6M | $1M | $0M | $0M |
| Total Shareholders' Equity | $127M | $78M | $172M | $82M | $111M | $64M | $90M | ($1M) | $93M | $78M | $122M | $169M | $104M | $35M | $8M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LRMR viewer.
About TickerBase · Data methodology & sources · Privacy · Terms